Genpharmasec Limited (BOM:531592)
India
· Delayed Price · Currency is INR 2.060
+0.030 (1.48%)
At close: May 5, 2025
Genpharmasec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 299.11 | 304.06 | 255.16 | 273.21 | 213.08 | 165.01 | Upgrade
|
| Revenue | 299.11 | 304.06 | 255.16 | 273.21 | 213.08 | 165.01 | Upgrade
|
| Revenue Growth (YoY) | 13.20% | 19.16% | -6.61% | 28.22% | 29.13% | 4298.73% | Upgrade
|
| Cost of Revenue | 237.7 | 242.33 | 233.97 | 265.65 | 192 | 152.36 | Upgrade
|
| Gross Profit | 61.41 | 61.73 | 21.18 | 7.55 | 21.07 | 12.65 | Upgrade
|
| Selling, General & Admin | 9.94 | 9.18 | 6.83 | 3.59 | 2.9 | 2.43 | Upgrade
|
| Other Operating Expenses | 40.35 | 52.09 | 11.67 | 9.18 | 6.23 | 3.68 | Upgrade
|
| Operating Expenses | 56.13 | 61.69 | 18.7 | 12.91 | 9.25 | 6.17 | Upgrade
|
| Operating Income | 5.27 | 0.04 | 2.48 | -5.36 | 11.82 | 6.48 | Upgrade
|
| Interest Expense | -4.85 | -4.09 | -0.56 | - | - | - | Upgrade
|
| Interest & Investment Income | 4.73 | 4.73 | 0.31 | 0.65 | 3.28 | 5.63 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.83 | 1.83 | 0.55 | 0.16 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 17.19 | -0 | 0.04 | 0.11 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 24.17 | 2.51 | 2.82 | -4.43 | 15.1 | 12.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.06 | Upgrade
|
| Pretax Income | 24.17 | 2.51 | 2.82 | -4.43 | 15.1 | 12.05 | Upgrade
|
| Income Tax Expense | 8.72 | 4.2 | -8.43 | -2.34 | 2.52 | 1.96 | Upgrade
|
| Earnings From Continuing Operations | 15.45 | -1.69 | 11.25 | -2.09 | 12.57 | 10.09 | Upgrade
|
| Minority Interest in Earnings | 0.44 | 0.44 | - | - | - | - | Upgrade
|
| Net Income | 15.89 | -1.26 | 11.25 | -2.09 | 12.57 | 10.09 | Upgrade
|
| Net Income to Common | 15.89 | -1.26 | 11.25 | -2.09 | 12.57 | 10.09 | Upgrade
|
| Net Income Growth | 38.97% | - | - | - | 24.57% | 337.06% | Upgrade
|
| Shares Outstanding (Basic) | 604 | 307 | 277 | 277 | 271 | 217 | Upgrade
|
| Shares Outstanding (Diluted) | 604 | 307 | 277 | 277 | 271 | 505 | Upgrade
|
| Shares Change (YoY) | - | 10.96% | - | 2.06% | -46.25% | 132.73% | Upgrade
|
| EPS (Basic) | 0.03 | -0.00 | 0.04 | -0.01 | 0.05 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.03 | -0.00 | 0.04 | -0.01 | 0.05 | 0.02 | Upgrade
|
| EPS Growth | - | - | - | - | 131.76% | 87.81% | Upgrade
|
| Free Cash Flow | - | -29.64 | -30.76 | -24.25 | -21.47 | 13.4 | Upgrade
|
| Free Cash Flow Per Share | - | -0.10 | -0.11 | -0.09 | -0.08 | 0.03 | Upgrade
|
| Gross Margin | 20.53% | 20.30% | 8.30% | 2.77% | 9.89% | 7.67% | Upgrade
|
| Operating Margin | 1.76% | 0.01% | 0.97% | -1.96% | 5.55% | 3.93% | Upgrade
|
| Profit Margin | 5.31% | -0.41% | 4.41% | -0.77% | 5.90% | 6.12% | Upgrade
|
| Free Cash Flow Margin | - | -9.75% | -12.05% | -8.88% | -10.08% | 8.12% | Upgrade
|
| EBITDA | 5.42 | 0.21 | 2.68 | -5.21 | 11.94 | 6.53 | Upgrade
|
| EBITDA Margin | 1.81% | 0.07% | 1.05% | -1.91% | 5.61% | 3.96% | Upgrade
|
| D&A For EBITDA | 0.14 | 0.17 | 0.2 | 0.14 | 0.13 | 0.05 | Upgrade
|
| EBIT | 5.27 | 0.04 | 2.48 | -5.36 | 11.82 | 6.48 | Upgrade
|
| EBIT Margin | 1.76% | 0.01% | 0.97% | -1.96% | 5.55% | 3.93% | Upgrade
|
| Effective Tax Rate | 36.07% | 167.63% | - | - | 16.70% | 16.26% | Upgrade
|
| Revenue as Reported | 322.85 | 310.62 | 256.16 | 274.13 | 216.35 | 170.64 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.